Pressemitteilung BoxID: 495286 (IQPC GmbH)
  • IQPC GmbH
  • Friedrichstrasse 94
  • 10117 Berlin
  • Ansprechpartner
  • +49 (30) 20913-0

Pharmaceutical Licensing 2012

(PresseBox) (Berlin, ) – In order to keep up with the continuous growth in the pharmaceutical market, the effectiveness of new business development strategies is crucial. An increasing proportion of revenues are expected to be generated from licensed products. As a result, licensing will become an ever more important component of the overall business development mix. Meet international experts at IQPC’s conference Pharmaceutical Licensing, 23 – 25 April 2012 in Berlin to discuss for example the impact of the impending 2011 patent cliff.

Licensing strategies are vital in avoiding portfolio or pipeline standstill. Consequently, drivers and resistors of licensing deals must be evaluated, and relationships with small pharma, biotech companies and academia must be built up and maintained. At the conference, 12 case studies and two panel discussions will illustrate the following topics:

• Relationship of R&D with business development
• Structure and procedure of licensing strategies
• Financial aspects of licensing: new partnerships and alternative deal-making, i.e. Alliance Management

Meet representatives of major market players at the conference, e.g. Bayer HealthCare, F. Hoffmann La Roche, Novartis Pharma, AstraZeneca UK and many more. For an interactive exchange of information, conference participants have the opportunity to attend the following workshops on Wednesday, 25 April 2012:

• “Licensing Trends – Success of licensing activity and beyond”
• “Strategic licensing as a cost-effective means”
• “Key legal fields affecting the life science sector in licensing”
• “Strategies at the edge of patent life”

Many networking breaks throughout the conference days give participants the opportunity to reach out and discuss their respective challenges and fields of interested.

For more information and interesting downloads, check